Cardiovascular Risks Associated with Progesterone Therapy

Introduction to Cardiovascular Risks

The American Heart Association recommends that combined estrogen plus progestin hormone therapy should not be initiated to prevent cardiovascular disease in postmenopausal women, and should not be continued for cardiovascular disease prevention, due to increased risk of coronary events, stroke, and venous thromboembolism 7
The European Society of Cardiology advises against routine use of hormone replacement therapy for chronic conditions, recommending current users to taper doses downward toward discontinuation 8

The Heart and Estrogen/Progestin Replacement Study demonstrated no cardiovascular benefit after 4.1 years of follow-up in 2,763 postmenopausal women with documented heart disease, with early harm followed by a non-significant trend toward benefit in years 4-5 1
Progesterone combined with estrogen increases stroke risk by approximately 41% in women with pre-existing cardiovascular risk factors such as hypertension, smoking, or age over 35 2
Current use of combined oral contraceptives containing progesterone is associated with a 1.5-1.9-fold increased risk of stroke 3, 4

Progesterone promotes leptin-mediated endothelial dysfunction in obese premenopausal women through aldosterone and endothelial mineralocorticoid receptors, which may further enhance sodium sensitivity 5, 6
Combined hormone therapy increases C-reactive protein levels, suggesting a proinflammatory effect that may contribute to cardiovascular risk 1
Increases in factor VII, prothrombin fragments 1 and 2, and activated protein C resistance occur with hormone therapy, along with decreased antithrombin III 1

Women with documented coronary heart disease should not receive progesterone-containing hormone therapy for cardiovascular protection 7, 8
Women with uterine fibroids have independent associations with hypertension and cardiovascular disease, making progesterone therapy particularly concerning in this population 5
Women with polycystic ovary syndrome already have elevated cardiovascular risk and should avoid additional progesterone-related cardiovascular burden 5, 6

Transdermal routes show lower thrombotic risk compared to oral administration, though this applies primarily to estrogen formulations 2
The cardiovascular data primarily reflect medroxyprogesterone acetate combined with conjugated equine estrogen; micronized progesterone may have different vascular effects, though large outcome trials are lacking 2